CNS Pharmaceuticals Statistics
Total Valuation
CNSP has a market cap or net worth of $3.59 million. The enterprise value is -$8.42 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, after market close.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNSP has 574,580 shares outstanding.
| Current Share Class | 574,580 |
| Shares Outstanding | 574,580 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +62.89% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 1.53% |
| Float | 525,994 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.22 |
| Quick Ratio | 8.77 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,009.79 |
Financial Efficiency
Return on equity (ROE) is -350.08% and return on invested capital (ROIC) is -214.51%.
| Return on Equity (ROE) | -350.08% |
| Return on Assets (ROA) | -114.68% |
| Return on Invested Capital (ROIC) | -214.51% |
| Return on Capital Employed (ROCE) | -118.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.09M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.33% in the last 52 weeks. The beta is 0.64, so CNSP's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -93.33% |
| 50-Day Moving Average | 8.32 |
| 200-Day Moving Average | 31.88 |
| Relative Strength Index (RSI) | 43.05 |
| Average Volume (20 Days) | 80,024 |
Short Selling Information
The latest short interest is 38,514, so 6.70% of the outstanding shares have been sold short.
| Short Interest | 38,514 |
| Short Previous Month | 40,508 |
| Short % of Shares Out | 6.70% |
| Short % of Float | 7.32% |
| Short Ratio (days to cover) | 1.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.58M |
| Pretax Income | -17.46M |
| Net Income | -15.46M |
| EBITDA | -15.57M |
| EBIT | -15.58M |
| Earnings Per Share (EPS) | -$85.41 |
Full Income StatementBalance Sheet
The company has $12.13 million in cash and $121,767 in debt, giving a net cash position of $12.01 million or $20.90 per share.
| Cash & Cash Equivalents | 12.13M |
| Total Debt | 121,767 |
| Net Cash | 12.01M |
| Net Cash Per Share | $20.90 |
| Equity (Book Value) | 13.12M |
| Book Value Per Share | 26.02 |
| Working Capital | 12.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.86 million and capital expenditures -$4,188, giving a free cash flow of -$20.86 million.
| Operating Cash Flow | -20.86M |
| Capital Expenditures | -4,188 |
| Free Cash Flow | -20.86M |
| FCF Per Share | -$36.31 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
